retatrutide trial results eli lilly The biggest weight-loss result ever recorded in a Phase 3 just landed — and it changes the conversation. Lilly's (a "triple agonist") delivered an average 28.3% body-weight Retatrutide Shows 28% Weight Loss

Furthermore, the FDA has issued warnings regarding mass-marketed, non-FDA-approved compounded GLP-1 alternatives

Who can prescribe weight loss injections after gallbladder removal in the UK

We understand how concerning it can be to come across misleading ads and false endorsements for diabetes products or services

A recent study demonstrated the protective role of GLP-1R receptors against hyperglycemia- induced endothelial to-mesenchymal transformation which is a crucial component of diabetic endothelial injury in cardiomyopathy, nephropathy, and retinopathy

GLP-1 therapy may also be appropriate for those seeking a medically supervised alternative to short-term dieting